[go: up one dir, main page]

FI875159L - Menetelmä terapeuttisesti käyttökelpoisten, /3S(Z)/-2-///1-(2-amino-4-tiatsolyyli)-2-//2,2-dimetyyli-4-okso-1-(sulfo-oksi)-3-atsetidinyyli/amino/-2-oksoetylideeni/amino/oksi/etikkahapon kiteisten dierytromysiini- ja dikoliinisuolojen valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten, /3S(Z)/-2-///1-(2-amino-4-tiatsolyyli)-2-//2,2-dimetyyli-4-okso-1-(sulfo-oksi)-3-atsetidinyyli/amino/-2-oksoetylideeni/amino/oksi/etikkahapon kiteisten dierytromysiini- ja dikoliinisuolojen valmistamiseksi Download PDF

Info

Publication number
FI875159L
FI875159L FI875159A FI875159A FI875159L FI 875159 L FI875159 L FI 875159L FI 875159 A FI875159 A FI 875159A FI 875159 A FI875159 A FI 875159A FI 875159 L FI875159 L FI 875159L
Authority
FI
Finland
Prior art keywords
amino
oxy
dierythromycin
oxoethylidene
azetidinyl
Prior art date
Application number
FI875159A
Other languages
English (en)
Swedish (sv)
Other versions
FI91757B (fi
FI91757C (fi
FI875159A0 (fi
Inventor
William Lawrence Parker
Edward Morton Cohen
William Henry Koster
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of FI875159A0 publication Critical patent/FI875159A0/fi
Publication of FI875159L publication Critical patent/FI875159L/fi
Publication of FI91757B publication Critical patent/FI91757B/fi
Application granted granted Critical
Publication of FI91757C publication Critical patent/FI91757C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI875159A 1986-12-19 1987-11-23 Menetelmä terapeuttisesti käyttökelpoisten, /3S(Z)/-2-///1-(2-amino-4-tiatsolyyli)-2-//2,2-dimetyyli-4-okso-1-(sulfo-oksi)-3-atsetidinyyli/amino/-2-oksoetylideeni/amino/oksi/etikkahapon kiteisten dierytromysiini- ja dikoliinisuolojen valmistamiseksi FI91757C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94428386 1986-12-19
US06/944,283 US4751220A (en) 1986-12-19 1986-12-19 Crystalline salts of [3S(Z)]-2[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy]acetic acid

Publications (4)

Publication Number Publication Date
FI875159A0 FI875159A0 (fi) 1987-11-23
FI875159L true FI875159L (fi) 1988-06-20
FI91757B FI91757B (fi) 1994-04-29
FI91757C FI91757C (fi) 1994-08-10

Family

ID=25481130

Family Applications (1)

Application Number Title Priority Date Filing Date
FI875159A FI91757C (fi) 1986-12-19 1987-11-23 Menetelmä terapeuttisesti käyttökelpoisten, /3S(Z)/-2-///1-(2-amino-4-tiatsolyyli)-2-//2,2-dimetyyli-4-okso-1-(sulfo-oksi)-3-atsetidinyyli/amino/-2-oksoetylideeni/amino/oksi/etikkahapon kiteisten dierytromysiini- ja dikoliinisuolojen valmistamiseksi

Country Status (25)

Country Link
US (1) US4751220A (fi)
JP (1) JP2511083B2 (fi)
KR (1) KR960007534B1 (fi)
AU (1) AU600536B2 (fi)
BE (1) BE1000625A3 (fi)
CA (1) CA1296717C (fi)
CH (1) CH674009A5 (fi)
DE (1) DE3743111C2 (fi)
DK (1) DK671487A (fi)
ES (1) ES2007766A6 (fi)
FI (1) FI91757C (fi)
FR (1) FR2610627B1 (fi)
GB (1) GB2199033B (fi)
GR (1) GR871937B (fi)
HU (1) HU197568B (fi)
IE (1) IE61325B1 (fi)
IL (1) IL84521A (fi)
IT (1) IT1233457B (fi)
LU (1) LU87076A1 (fi)
NL (1) NL193639C (fi)
NZ (1) NZ222599A (fi)
PH (1) PH23170A (fi)
PT (1) PT86403B (fi)
SE (1) SE467782B (fi)
ZA (1) ZA879031B (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
AU2002359721A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
CN101724000B (zh) * 2008-10-29 2012-05-30 广东东阳光药业有限公司 一种红霉素的结晶方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN113975396B (zh) * 2021-11-09 2022-11-29 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES376380A1 (es) * 1970-01-30 1972-04-16 Roger Lab Procedimiento de obtencion de un nuevo derivado de eritro- micina.
AU8364875A (en) * 1974-08-21 1977-02-10 Hoffmann La Roche Choline and n-methyl-d-glucamine salts of amoxycillin
US4337197A (en) * 1980-10-31 1982-06-29 E. R. Squibb & Sons, Inc. O-sulfated β-lactam hydroxamic acids and intermediates
US4533660A (en) * 1980-10-31 1985-08-06 E. R. Squibb & Sons, Inc. Antibacterial O-sulfated β-lactam hydroxamic acids
US4638061A (en) * 1985-01-28 1987-01-20 E. R. Squibb & Sons, Inc. [3S(Z)]-2-[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy] acetic acid and intermediate

Also Published As

Publication number Publication date
HUT45998A (en) 1988-09-28
IL84521A (en) 1992-02-16
JPS63165381A (ja) 1988-07-08
LU87076A1 (fr) 1988-07-14
FR2610627B1 (fr) 1989-12-01
FI91757B (fi) 1994-04-29
NL193639C (nl) 2000-05-04
IT8722908A0 (it) 1987-12-07
IE61325B1 (en) 1994-11-02
DK671487A (da) 1988-06-20
AU8185787A (en) 1988-06-23
GR871937B (en) 1988-04-26
ES2007766A6 (es) 1989-07-01
HU197568B (en) 1989-04-28
IL84521A0 (en) 1988-04-29
BE1000625A3 (fr) 1989-02-21
NL193639B (nl) 2000-01-03
SE467782B (sv) 1992-09-14
DK671487D0 (da) 1987-12-18
FR2610627A1 (fr) 1988-08-12
CA1296717C (en) 1992-03-03
NZ222599A (en) 1989-09-27
IT1233457B (it) 1992-04-02
AU600536B2 (en) 1990-08-16
FI91757C (fi) 1994-08-10
KR880007528A (ko) 1988-08-27
IE873447L (en) 1988-06-19
DE3743111C2 (de) 1996-04-04
GB2199033B (en) 1990-10-24
GB2199033A (en) 1988-06-29
CH674009A5 (fi) 1990-04-30
PT86403B (pt) 1990-11-20
DE3743111A1 (de) 1988-06-30
GB8727048D0 (en) 1987-12-23
JP2511083B2 (ja) 1996-06-26
PT86403A (en) 1988-01-01
FI875159A0 (fi) 1987-11-23
KR960007534B1 (ko) 1996-06-05
ZA879031B (fi) 1988-05-27
SE8705068L (sv) 1988-06-20
SE8705068D0 (sv) 1987-12-18
PH23170A (en) 1989-05-19
NL8703047A (nl) 1988-07-18
US4751220A (en) 1988-06-14

Similar Documents

Publication Publication Date Title
FI906438L (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten A-nor-steroidi-3-karboksyylihappojohdannaisten valmistamiseksi
FI913137L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4"-deoksi-4"-epi-metyyliaminoavermekitiinisuolojen valmistamiseksi
FI890282L (fi) Menetelmä terapeuttisesti käyttökelpoisten 23,24-didehydro-25-hydroksikalsiferolijohdannaisten valmistamiseksi
GB8811645D0 (en) Novel 2-(5-fluoronicotinoyl)acetic acid derivative/salts thereof
FI875666L (fi) Menetelmä terapeuttisesti aktiivisen kinoliiniyhdisteen valmistamiseksi
FI883261L (fi) Menetelmä somatostatiinia sisältävän farmaseuttisen ainekoostumuksen valmistamiseksi
PH22924A (en) Optically pure monohydrate of s-(-)-1-propyl-2',6' pipecoloxylidide hydrochloride and a process for its preparation
FI875159L (fi) Menetelmä terapeuttisesti käyttökelpoisten, /3S(Z)/-2-///1-(2-amino-4-tiatsolyyli)-2-//2,2-dimetyyli-4-okso-1-(sulfo-oksi)-3-atsetidinyyli/amino/-2-oksoetylideeni/amino/oksi/etikkahapon kiteisten dierytromysiini- ja dikoliinisuolojen valmistamiseksi
AU1210688A (en) Crystallized cephem-acid addition salts, and a process for the preparation thereof
FI884611L (fi) Menetelmä -/4-(1,1-dimetyylietyyli)fenyyli/-4-(hydroksidifenyylimetyyli)-1-piperidiinibutanolin farmaseuttisen koostumuksen valmistamiseksi
PT87672A (pt) Process for preparing a pharmaceutical composition
FI900145L (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
SE8600355L (sv) Forfarande for framstellning av 4,4-dialkyl-2-azetidinoner
FI903030A0 (fi) Menetelmä polyprenyyliyhdistettä sisältävän farmaseuttisen koostumuksen valmistamiseksi
FI874473L (fi) Menetelmä valmistaa farmakologisesti arvokasta fenoksietikkahappojohdosta
HUT49846A (en) Process for producing n-(3',4'-dimethoxycinnamoyl)-anthranilic acid (tranilast)
FI891410L (fi) Menetelmä flufeeniaminohapon 2-(2hydroksietoksi)etanoliesterin valmistamiseksi
IT1219485B (it) Apparecchio di pulitura a piu' piani per mietitrebbia
ZA908298B (en) Optically active thiazetoquinoline-3-carboxylic acid compound,method for preparation thereof,and a pharmaceutical composition comprising the same
AU4552489A (en) Amine salts of 1,4,2-oxazaphospholidine-4-acetic acid, 2-alkoxy-2-oxides
EP0236948A3 (en) Novel compounds wk-142 and process for preparing the same
EP0393782A3 (en) Catecholamine esters
AU2486392A (en) Process for producing optically active 1,4-dihydropyridine compound

Legal Events

Date Code Title Description
BB Publication of examined application
BB Publication of examined application
MM Patent lapsed

Owner name: E.R. SQUIBB & SONS, INC.